Epizyme, Inc. is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment. Epizyme has two programs in clinical development. Our lead program, EPZ-6438, is in Phase 1/2 development for Non-Hodgkin Lymphoma and a subset of genetically defined tumors including malignant rhabdoid tumors, epithelioid sarcomas, and synovial sarcomas. Epizyme owns worldwide rights to EPZ-6438 outside of Japan, and plans to start a broad Phase 2 clinical development program in 2015. Epizyme‘s management team, scientific advisors, and board of directors are recognized leaders in the scientific community and biopharmaceutical industry. Working together, we are committed to developing novel epigenetic therapeutics for cancer patients. Epizyme is headquartered in Cambridge, MA.

Company Growth (employees)
Cambridge, US
Size (employees)
89 (est)
Epizyme was founded in 2007 and is headquartered in Cambridge, US

Key People at Epizyme

Robert A. Copeland

Robert A. Copeland

Executive Vice President and Chief Scientific Officer

Epizyme Office Locations

Epizyme has an office in Cambridge
Cambridge, US (HQ)
400 Technology Square

Epizyme Data and Metrics

Epizyme Financial Metrics

Epizyme's revenue was reported to be $8 m in FY, 2016 which is a 213% increase from the previous period.
$, USD

Revenue (FY, 2016)

8 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(110.2 m)

EBIT (FY, 2016)

(111.8 m)

Market capitalization (23-Jun-2017)

857.9 m

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

77.9 m
Epizyme's current market capitalization is $857.9 m.
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


68.5 m41.4 m2.6 m8 m

Revenue growth, %


Operating expense total

71.6 m96.5 m135.1 m119.8 m


(3.1 m)(55.1 m)(132.5 m)(111.8 m)

EBIT margin, %


Interest income

74 k95 k

Pre tax profit

(3.1 m)(54.9 m)(132.4 m)(110.2 m)

Income tax expense

349 k109 k

Net Income

(3.5 m)(55 m)(132.4 m)(110.2 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


123.6 m190.1 m208.3 m77.9 m

Accounts Receivable

33.7 m2.1 m262 k23 k


2.4 m2.8 m4.5 m6.5 m

Current Assets

159.7 m195 m213.1 m248.7 m


2.2 m3.6 m4.1 m3.1 m

Total Assets

163 m199.2 m217.9 m252.4 m

Accounts Payable

4.7 m8.3 m4.7 m5 m

Current Liabilities

34.6 m17 m18.4 m21.6 m

Additional Paid-in Capital

160.4 m271.4 m413 m555.5 m

Retained Earnings

(56.1 m)(111.1 m)(243.5 m)(353.7 m)

Total Equity

104.3 m160.3 m169.5 m201.7 m

Financial Leverage

1.6 x1.2 x1.3 x1.3 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.5 m)(55 m)(132.4 m)(110.2 m)

Depreciation and Amortization

703 k742 k1.4 m1.6 m

Accounts Receivable

(32 m)31.6 m1.8 m239 k


(1.5 m)(419 k)(1.6 m)(1.5 m)

Accounts Payable

1.6 m3.6 m(3.6 m)341 k

Cash From Operating Activities

(53.7 m)(35.4 m)(72.9 m)(96.4 m)

Purchases of PP&E

(630 k)(2.2 m)(183 k)(624 k)

Cash From Investing Activities

(630 k)(2.2 m)(40.2 m)(165.4 m)

Cash From Financing Activities

79.9 m104.1 m131.3 m131.4 m

Income Taxes Paid

963 k963 k963 k
Y, 2016

Financial Leverage

1.3 x

Epizyme Market Value History

Epizyme Online and Social Media Presence

Epizyme Company Life and Culture

You may also be interested in